Development and validation of longitudinal c-reactive protein as dynamic response predictor for PD-L1 blockade in advanced NSCLC: Findings from four atezolizumab clinical trials.

被引：0

作者：

Zhou, Jian-Guo

Chen, Xiaofei

Wong, Ada Hang-Heng

Wang, Haitao

Tan, Fangya

He, Si-Si

Shen, Gang

Wang, YunJia

Wang, Ruihong

Carr, Shamus R.

Frey, Benjamin

Fietkau, Rainer

Hecht, Markus

Ma, Hu

Schrump, David S.

Gaipl, Udo S.

机构：

[1] Zunyi Med Univ, Affiliated Hosp 2, Zunyi, Guizhou, Peoples R China

[2] Sanofi, Bridgewater, NJ USA

[3] AW Med Co Ltd, Macau, Peoples R China

[4] Natl Inst Hlth, Natl Canc Inst, Bethesda, MD USA

[5] Harrisburg Univ Sci Technol, Harrisburg, PA USA

[6] Zunyi Med Univ, Affiliated Hosp 2, Zunyi City, Peoples R China

[7] Friedrich Alexan Univ Erlangen Nurnberg, Univ Erlangen, Dept Radiat Oncol, Erlangen, Germany

[8] Natl Inst Hlth, Natl Canc Inst, Bethesda, MD USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e21113

引用

页数：1

共 11 条

[1] Development and clinical validation of a quantitative mass spectrometric assay for PD-L1 protein in FFPE NSCLC samples
An, E.
Liao, W.
Thyparambil, S.
Rodriguez, J.
Salgia, R.
Wistuba, I.
Burrows, J.
Hembrough, T.
EUROPEAN JOURNAL OF CANCER, 2014, 50 : 159 - 159
[2] Development and clinical validation of a quantitative mass spectrometric assay for PD-L1 protein in FFPE NSCLC samples.
An, Eunkyung
Liao, Wei-Li
Thyparambil, Sheeno
Rodriguez, Jaime
Salgia, Ravi
Wistuba, Ignacio I.
Burrows, Jon
Hembrough, Todd
CLINICAL CANCER RESEARCH, 2014, 20
[3] C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma
Kluemper, Niklas
Sikic, Danijel
Saal, Jonas
Buettner, Thomas
Goldschmidt, Franziska
Jarczyk, Jonas
Becker, Philippe
Zeuschner, Philip
Weinke, Maximilian
Kalogirou, Charis
Breyer, Johannes
Burger, Maximilian
Nuhn, Philipp
Tully, Karl
Roghmann, Florian
Bolenz, Christian
Zengerling, Friedemann
Wirtz, Ralph M.
Muders, Michael
Kristiansen, Glen
Bald, Tobias
Ellinger, Joerg
Wullich, Bernd
Hoelzel, Michael
Hartmann, Arndt
Erben, Philipp
Ritter, Manuel
Eckstein, Markus
EUROPEAN JOURNAL OF CANCER, 2022, 167 : 13 - 22
[4] Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
Teo, Min Yuen
Seier, Kenneth
Ostrovnaya, Irina
Regazzi, Ashley M.
Kania, Brooke E.
Moran, Meredith M.
Cipolla, Catharine K.
Bluth, Mark J.
Chaim, Joshua
Al-Ahmadie, Hikmat
Snyder, Alexandra
Carlo, Maria I.
Solit, David B.
Berger, Michael F.
Funt, Samuel
Wolchok, Jedd D.
Iyer, Gopa
Bajorin, Dean F.
Callahan, Margaret K.
Rosenberg, Jonathan E.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) : 1685 - +
[5] Longitudinal C-reactive protein (CRP) as an individualized dynamic predictor for metastatic cancer patients treated with immune checkpoint inhibitors: Findings from the prospective ST-ICI cohort.
Zhou, Jian-Guo
Ma, Hu
Gaipl, Udo
Frey, Benjamin
Hecht, Markus
Fietkau, Rainer
CANCER RESEARCH, 2021, 81 (13)
[6] Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+NSCLC: Results from the randomized OAK study
Gadgeel, S.
Kowanetz, M.
Zou, W.
Hirsch, F. R.
Kerr, K. M.
Gandara, D. R.
Barlesi, F.
Park, K.
McCleland, M.
Koeppen, H.
Ballinger, M.
Sandler, A.
Hegde, P. S.
Rittmeyer, A.
ANNALS OF ONCOLOGY, 2017, 28
[7] Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
Chae, Young Kwang
Arya, Ayush
Iams, Wade
Cruz, Marcelo R.
Chandra, Sunandana
Choi, Jaehyuk
Giles, Francis
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[8] SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, as first-line therapy for PD-L1+advanced/metastatic NSCLC: Data from a clinical expansion cohort of a phase I study
Feng, J.
Chen, J.
Li, K.
Li, X.
Min, X.
Li, B.
Lin, L.
Fang, Y.
Sun, Y.
Zhu, B.
Wang, Q.
Wang, L.
Zou, J.
Liu, P.
ANNALS OF ONCOLOGY, 2021, 32 : S995 - S995
[9] Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN Solid Tumor phase 1b trial: Safety, clinical activity, and PD-L1 expression.
Verschraegen, Claire F.
Chen, Franklin
Spigel, David R.
Iannotti, Nicholas
McClay, Edward Francis
Redfern, Charles H.
Bennouna, Jaafar
Taylor, Matthew H.
Kaufman, Howard
Kelly, Karen
Bajars, Marcis
von Heydebreck, Anja
Cuillerot, Jean-Marie
Jerusalem, Guy Heinrich Maria
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[10] Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
Cortellini, Alessio
Brunetti, Leonardo
Di Fazio, Giuseppina Rita
Garbo, Edoardo
Pinato, David J.
Naidoo, Jarushka
Katz, Artur
Loza, Monica
Neal, Joel W.
Genova, Carlo
Gettinger, Scott
Kim, So Yeon
Jayakrishnan, Ritujith
El Zarif, Talal
Russano, Marco
Pecci, Federica
Di Federico, Alessandro
Awad, Mark
Alessi, Joao, V
Montrone, Michele
Owen, Dwight Hall
Signorelli, Diego
Fidler, Mary Jo
Li, Mingjia
Camerini, Andrea
De Giglio, Andrea
Young, Lauren
Vincenzi, Bruno
Metro, Giulio
Passiglia, Francesco
Yendamuri, Sai
Guida, Annalisa
Ghidini, Michele
Awosika, Nichola O.
Napolitano, Andrea
Fulgenzi, Claudia A. M.
Grisanti, Salvatore
Grossi, Francesco
D'Incecco, Armida
Josephides, Eleni
Van Hemelrijck, Mieke
Russo, Alessandro
Gelibter, Alain
Spinelli, Gianpaolo
Verrico, Monica
Tomasik, Bartlomiej
Giusti, Raffaele
Newsom-Davis, Thomas
Bria, Emilio
Sebastian, Martin
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (02)

← 1 2 →